Effects of acute 17alpha-methyltestosterone, acute 17beta-estradiol, and chronic 17alpha-methyltestosterone on dopamine, norepinephrine and serotonin levels in the pituitary, hypothalamus and telencephalon of rainbow trout (Oncorhynchus mykiss).
This study investigated: (a) the effects of acute 17alpha-methyltestosterone (MT) or 17beta-estradiol (E(2)) administration on norepinephrine (NE), dopamine (DA), serotonin (5-HT), 3,4, dihydroxyphenylacetic acid (DOPAC), and 5-hydroxyindoleacetic acid (5-HIAA) contents in the hypothalamus, telencephalon and pituitary of previtellogenic female rainbow trout Oncorhynchus mykiss, and (b) the effects of chronic MT administration on the levels of these neurotransmitters in these brain regions in immature male rainbow trout. The acute administration of MT induced a significant decrease in pituitary levels of DOPAC as well as in the DOPAC/DA ratio. On the other hand, the acute administration of E(2) induced an increase in pituitary 5-HT levels as well as a decrease in the 5-HIAA/5-HT ratio. In a second experiment, 20 mg MT per kilogram body weight was implanted for 10, 20 or 40 days into sexually immature male rainbow trout. Implanted rainbow trout showed increased testosterone and decreased E(2) levels. In the pituitary, MT induced long-term decreases in NE, DA, DOPAC and 5-HT levels, as well as in the DOPAC/DA ratio. Hypothalamic and telencephalic DA, NE and 5-HT levels were not affected by MT implantation. However, 5-HIAA levels and the 5-HIAA/5-HT ratio were reduced by MT implantation in both brain regions. These results show that chronic treatment with MT exerts both long-term and region-specific effects on NE, DA, and 5-HT contents and metabolism, and thus that this androgen could inhibit pituitary catecholamine and 5-HT synthesis. A possible role for testosterone in the control of pituitary dopaminergic activity and gonadotropin II release is also discussed.
Hernandez-Rauda
R
R
Laboratorio de Fisioloxía Animal (Dpto de Fisioloxía), Facultade de Bioloxía, Universidade de Santiago de Compostela, E-15782 Santiago de Compostela, Spain.
Aldegunde
M
M
D000818:Animals; D004298:Dopamine / Q000378:metabolism; D004343:Drug Implants; D004958:Estradiol / Q000008:administration & dosage*; D005260:Female; D007031:Hypothalamus / Q000378:metabolism*; D007274:Injections, Intraperitoneal; D008297:Male; D008777:Methyltestosterone / Q000008:administration & dosage*; D018377:Neurotransmitter Agents / Q000378:metabolism*; D009638:Norepinephrine / Q000378:metabolism; D017686:Oncorhynchus mykiss / Q000378:metabolism*; D010902:Pituitary Gland / Q000378:metabolism*; D012701:Serotonin / Q000378:metabolism; D013687:Telencephalon / Q000378:metabolism*
D004343:Drug Implants; D018377:Neurotransmitter Agents; D012701:Serotonin; D004958:Estradiol; D008777:Methyltestosterone; D004298:Dopamine; D009638:Norepinephrine